Importantly, survivin found extracellularly creates a more erosive disease in patients with rheumatoid arthritis (Bokarewa et al, 2005) and in our cancer cell culture models, parameters that are considered clinically unfavourable in cancer patients: proliferative advantage, enhanced resistance to therapy, and enhanced metastatic potential. Here, BIRC5 is linked to rheumatoid arthritis.